Recursion Sustainability Profile
Recursion Pharmaceuticals, commonly referred to as Recursion, is a pioneering biotechnology company headquartered in the United States. Founded in 2013, Recursion has rapidly established itself at the forefront of drug discovery and development, leveraging advanced machine learning and high-throughput biology to transform the way diseases are treated. With a strong operational presence in major regions across the US, Recursion focuses on utilising its unique platform to identify novel therapeutics for a range of conditions, particularly in rare diseases and oncology. The company’s innovative approach combines vast biological data with cutting-edge technology, setting it apart in the competitive biotech landscape. Notable achievements include significant partnerships and collaborations that enhance its market position, underscoring Recursion's commitment to revolutionising healthcare through data-driven insights and transformative therapies.
DitchCarbon Score
How does Recursion's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Recursion's score of 24 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Recursion's reported carbon emissions
In 2022, Recursion Pharmaceuticals, Inc. reported total carbon emissions of approximately 1,249,580 kg CO2e, comprising 269,260 kg CO2e from Scope 1 and 980,320 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data. Recursion has not set specific reduction targets or initiatives as part of its climate commitments, and there are no documented climate pledges or SBTi targets. The emissions data is not cascaded from a parent company, indicating that these figures are solely from Recursion Pharmaceuticals, Inc. The company operates within the biotechnology sector, which is increasingly focusing on sustainability and carbon reduction. However, without specific targets or commitments, Recursion's approach to climate action remains unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 269,260 |
| Scope 2 | 980,320 |
| Scope 3 | - |
How Carbon Intensive is Recursion's Industry?
How Carbon Intensive is Recursion's Location?
Recursion's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Recursion has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.